Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day
September 14 2023 - 7:30AM
Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage
biotechnology company advancing differentiated biologics for the
treatment of atopic dermatitis (AD), chronic obstructive pulmonary
disease (COPD) and other inflammatory and immunology (I&I)
indications, today announced that members of its management will
participate in a fireside chat at the 2023 Stifel Virtual I&I
Day on Wednesday, September 20th, 2023 at 9:30 a.m. ET.
A live and archived webcast of the virtual fireside chat will be
available via the News & Events page in the Investors section
of the Apogee Therapeutics website.
About Apogee Therapeutics
Apogee Therapeutics is a clinical-stage biotechnology company
seeking to develop differentiated biologics for the treatment of
atopic dermatitis (AD), chronic obstructive pulmonary disease
(COPD) and other inflammatory and immunology indications with high
unmet need. Apogee’s antibody programs are designed to overcome
limitations of existing therapies by targeting well-established
mechanisms of action and incorporating advanced antibody
engineering properties, including half-life extension. The
company’s two most advanced programs are APG777 and APG808, which
are being initially developed for the treatment of AD and COPD,
respectively. Based on a broad pipeline and depth of expertise, the
company believes it can deliver value and meaningful benefit to
patients underserved by today’s standard of care. For more
information, please visit www.apogeetherapeutics.com.
Investor Contacts:
Noel KurdiVP of Investor RelationsApogee
Therapeuticsnoel.kurdi@apogeetherapeutics.com
Alex StrausTHRUST Strategic Communicationsalex@thrustsc.com
Media Contact:
Dan Budwick 1AB Mediadan@1abmedia.com
Apogee Therapeutics (NASDAQ:APGE)
Historical Stock Chart
From Apr 2024 to May 2024
Apogee Therapeutics (NASDAQ:APGE)
Historical Stock Chart
From May 2023 to May 2024